ecancer
The International Agency for Research on Cancer has estimated that about half of all cancers could be avoided if current knowledge was adequately implemented.
ecancer is a UK charity, working tirelessly to ensure current knowledge is properly shared. Our mission is to raise the standards of global cancer care through education.
We were founded in 2007 by two inspirational oncologists, Prof Gordon McVie and Prof Umberto Veronesi. Frustrated by global inequalities in access to education and research, they were driven to create an open platform to share knowledge that would help raise the standards of cancer care - ecancer.org.
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC
Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers
Independent clones in CLL show oligoclonality and early evolution patterns
Ordronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results
The combination of acimtamig and AlloNK® therapy demonstrates promising efficacy in R/R cHL
POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma
The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-...
Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience i...
Bexmarilimab plus azacitidine shows promising response in relapse refractory myelodysplasia
Ключевые выводы исследований рака легких на конференции ASCO 2025
Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC
Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance
Key insights from head and neck research at ASCO 2025
Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer
Catequentinib improves PFS vs placebo in advanced or metastatic leiomyosarcoma
AI improves accuracy in identifying HER2-low and HER2-ultralow breast cancers
Primary cytoreductive surgery shows PFS benefit in advanced ovarian cancer
Disparities in mammogram screening amongst LGBTQ+ populations
Tumour microenvironment and circulating biomarkers predict response to immunotherapy in advanced...
HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC
ctDNA-guided chemo escalation does not improve recurrence-free survival in stage III colon cancer
ASCO 2025: Breast cancer treatment highlights
QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC
Long-term infusion of dinutuximab beta improves survival in high-risk neuroblastoma
Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type mCRC
Ropeginterferon Alfa-2b shows superior efficacy and safety over anagrelide in essential thromboc...
Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible metastatic urotheli...
Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy
Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in Morocco